Table 3 Diagnostic performance of the top 11 5-marker combinations*.
No. | Autoantibodies | Training set | Validation set | ||||
|---|---|---|---|---|---|---|---|
Youden’s index | sensitivity [95% CI] in % | specificity [95% CI] in % | Youden’s index | sensitivity [95% CI] in % | specificity [95% CI] in % | ||
1 | anti-MAGEA4 + anti-CTAG1 + anti-TP53 + anti-ERBB2_C + anti-SDCCAG8 | 0.23 | 34 [27–41] | 89 [85–93] | 0.19 | 32 [25–40] | 87 (78-92) |
2 | anti-MAGEA4 + anti-CTAG1 + anti-TP53 + anti-ERBB2_C + anti-ANXA4 | 0.22 | 32 [25–40] | 90 [85–93] | 0.18 | 32 [25–39] | 87 (78-92) |
3 | anti-MAGEA4 + anti-CTAG1 + anti-TP53 + anti-SDCCAG8 + anti-GRINA | 0.22 | 32 [25–39] | 90 [86–93] | 0.18 | 32 [25–39] | 87 (78-92) |
4 | anti-MAGEA4 + anti-CTAG1 + anti-TP53 + anti-SDCCAG8 + anti-TPM3_iso3 | 0.22 | 32 [25–40] | 89 [85–93] | 0.17 | 30 [23–38] | 87 (78-92) |
5 | anti-MAGEA4 + anti-CTAG1 + anti-TP53 + anti-ERBB2_C + anti-DDX53 | 0.22 | 32 [25–40] | 89 [85–93] | 0.21 | 32 [25–40] | 89 (81-94) |
6 | anti-MAGEA4 + anti-CTAG1 + anti-TP53 + anti-ERBB2_C + anti-PSCA | 0.21 | 30 [24–38] | 91 [87–94] | 0.21 | 31 [24–39] | 90 (82-94) |
7 | anti-MAGEA4 + anti-CTAG1 + anti-TP53 + anti-ERBB2_C + anti-FOLH1_iso1 | 0.21 | 30 [24–38] | 91 [87–94] | 0.19 | 29 [23–37] | 90 (82-94) |
8 | anti-MAGEA4 + anti-CTAG1 + anti-TP53 + anti-ERBB2_C + anti-FOLH1_iso7 | 0.21 | 30 [24–38] | 91 [87–94] | 0.19 | 29 [23–37] | 90 (82-94) |
9 | anti-MAGEA4 + anti-CTAG1 + anti-TP53 + anti-ERBB2_C + anti-DCT | 0.21 | 30 [24–38] | 91 [87–94] | 0.19 | 29 [23–37] | 90 (82-94) |
10 | anti-MAGEA4 + anti-CTAG1 + anti-TP53 + anti-SDCCAG8 + anti-DDX53 | 0.21 | 32 [25–39] | 90 [85–93] | 0.19 | 32 [25–39] | 88 (80-93) |
11 | anti-MAGEA4 + anti-CTAG1 + anti-TP53 + anti-ERBB2_C + anti-IGF2BP1 | 0.21 | 32 [25–39] | 90 [85–93] | 0.16 | 33 [26–41] | 84 (75-90) |
